{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T23:08:50Z","timestamp":1788908930379,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":76,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-026-01523-w","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:04:52Z","timestamp":1782345892000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of post-transplant brentuximab vedotin maintenance by pre-transplant disease status in relapsed\/refractory classic Hodgkin lymphoma"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7892-2625","authenticated-orcid":false,"given":"Sanjal H.","family":"Desai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Geyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5902-8882","authenticated-orcid":false,"given":"Levi","family":"Pederson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Spinner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9325-432X","authenticated-orcid":false,"given":"Veronika","family":"Bachanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Evens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6148-5177","authenticated-orcid":false,"given":"Gaurav","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0459-6609","authenticated-orcid":false,"given":"Brad","family":"Kahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Dorritie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Azzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaishalee P.","family":"Kenkre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendon","family":"Fusco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7456-0623","authenticated-orcid":false,"given":"Nuttavut","family":"Sumransub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haris","family":"Hatic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raya","family":"Saba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uroosa","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elyse I.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harsh","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Wagner-Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepa","family":"Jagadeesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristie A.","family":"Blum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Diefenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddharth","family":"Iyengar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KC","family":"Rappazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firas","family":"Baidoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjana H.","family":"Advani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Mocikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Sykorova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jozef","family":"Michalka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9861-3117","authenticated-orcid":false,"given":"Vit","family":"Prochazka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana N.","family":"Micallef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"1523_CR1","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1056\/NEJMoa2206125","volume":"387","author":"SM Ansell","year":"2022","unstructured":"Ansell SM, Radford J, Connors JM, Dlugosz-Danecka M, Kim WS, Gallamini A, et al. Overall survival with brentuximab vedotin in stage III or IV Hodgkin\u2019s lymphoma. N Engl J Med. 2022;387:310\u201320.","journal-title":"N Engl J Med"},{"key":"1523_CR2","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1056\/NEJMoa1708984","volume":"378","author":"JM Connors","year":"2018","unstructured":"Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma. N Engl J Med. 2018;378:331\u201344.","journal-title":"N Engl J Med"},{"key":"1523_CR3","first-page":"221","volume":"20","author":"A Josting","year":"2002","unstructured":"Josting A, Franklin J, May M, Koch P, Beykirch MK, Heinz J, et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin\u2019s lymphoma registered in the database of the German Hodgkin\u2019s lymphoma study group. J Clin Oncol. 2002;20:221\u201330.","journal-title":"J Clin Oncol"},{"key":"1523_CR4","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","volume":"341","author":"DC Linch","year":"1993","unstructured":"Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin\u2019s disease: results of a BNLI randomised trial. Lancet. 1993;341:1051\u20134.","journal-title":"Lancet"},{"key":"1523_CR5","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","volume":"359","author":"N Schmitz","year":"2002","unstructured":"Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: a randomised trial. Lancet. 2002;359:2065\u201371.","journal-title":"Lancet"},{"key":"1523_CR6","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.bbmt.2017.09.006","volume":"24","author":"V Prochazka","year":"2018","unstructured":"Prochazka V, Gawande RS, Cayci Z, Froelich JW, Cao Q, Wilke C, et al. Positron emission tomography-based assessment of metabolic tumor volume predicts survival after autologous hematopoietic cell transplantation for Hodgkin lymphoma. Biol Blood Marrow Transplant. 2018;24:64\u201370.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1523_CR7","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.bbmt.2006.06.006","volume":"12","author":"NS Majhail","year":"2006","unstructured":"Majhail NS, Weisdorf DJ, Defor TE, Miller JS, McGlave PB, Slungaard A, et al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin\u2019s lymphoma. Biol Blood Marrow Transplant. 2006;12:1065\u201372.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1523_CR8","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1093\/annonc\/mdn052","volume":"19","author":"B Sirohi","year":"2008","unstructured":"Sirohi B, Cunningham D, Powles R, Murphy F, Arkenau T, Norman A, et al. Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin\u2019s lymphoma. Ann Oncol. 2008;19:1312\u20139.","journal-title":"Ann Oncol"},{"key":"1523_CR9","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1093\/annonc\/mdi119","volume":"16","author":"A Sureda","year":"2005","unstructured":"Sureda A, Constans M, Iriondo A, Arranz R, Caballero MD, Vidal MJ, et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin\u2019s lymphoma autografted after a first relapse. Ann Oncol. 2005;16:625\u201333.","journal-title":"Ann Oncol"},{"key":"1523_CR10","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","volume":"385","author":"CH Moskowitz","year":"2015","unstructured":"Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, et al. Brentuximab vedotin as maintenance therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385:1853\u201362.","journal-title":"Lancet"},{"key":"1523_CR11","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1182\/blood-2018-07-861641","volume":"132","author":"CH Moskowitz","year":"2018","unstructured":"Moskowitz CH, Walewski J, Nademanee A, Masszi T, Agura E, Holowiecki J, et al. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood. 2018;132:2639\u201342.","journal-title":"Blood"},{"key":"1523_CR12","doi-asserted-by":"publisher","first-page":"5458","DOI":"10.1182\/bloodadvances.2024013743","volume":"8","author":"N Epperla","year":"2024","unstructured":"Epperla N, Huang Y, Cashen AF, Vaughn JL, Hanel W, Badar T, et al. Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation. Blood Adv. 2024;8:5458\u201366.","journal-title":"Blood Adv"},{"key":"1523_CR13","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/bjh.14245","volume":"175","author":"GL Shah","year":"2016","unstructured":"Shah GL, Yahalom J, Matasar MJ, Verwys SL, Goldman DA, Bantilan KS, et al. Risk factors predicting outcomes for primary refractory Hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantation. Br J Haematol. 2016;175:440\u20137.","journal-title":"Br J Haematol"},{"key":"1523_CR14","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1002\/ajh.26827","volume":"98","author":"SH Desai","year":"2023","unstructured":"Desai SH, Spinner MA, David K, Bachanova V, Goyal G, Kahl B, et al. Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed\/refractory classic Hodgkin lymphoma. Am J Hematol. 2023;98:464\u201371.","journal-title":"Am J Hematol"},{"key":"1523_CR15","doi-asserted-by":"crossref","unstructured":"Desai SH, Moskowitz AJ, Merryman RW, Shah HR, Pederson LD, Geyer S, et al. PD-1-based combinations before autologous transplant are associated with improved outcomes in classical Hodgkin lymphoma. Blood. 2026;147:1125\u201334.","DOI":"10.1182\/blood.2025030151"},{"key":"1523_CR16","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1002\/sim.5984","volume":"33","author":"PC Austin","year":"2014","unstructured":"Austin PC. The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments. Stat Med. 2014;33:1242\u201358.","journal-title":"Stat Med"},{"key":"1523_CR17","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1016\/j.bbmt.2018.05.026","volume":"24","author":"A Nademanee","year":"2018","unstructured":"Nademanee A, Sureda A, Stiff P, Holowiecki J, Abidi M, Hunder N, et al. Safety analysis of brentuximab vedotin from the phase III AETHERA trial in Hodgkin lymphoma in the post-transplant maintenance setting. Biol Blood Marrow Transplant. 2018;24:2354\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1523_CR18","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.3324\/haematol.2023.282780","volume":"108","author":"CB Wagner","year":"2023","unstructured":"Wagner CB, Boucher K, Nedved A, Micallef IN, Desai S, Hatic H, et al. Effect of cumulative dose of brentuximab vedotin maintenance in relapsed\/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomes. Haematologica. 2023;108:3025\u201332.","journal-title":"Haematologica"},{"key":"1523_CR19","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.3324\/haematol.2021.279564","volume":"107","author":"A Marouf","year":"2022","unstructured":"Marouf A, Cottereau AS, Kanoun S, Deschamps P, Meignan M, Franchi P, et al. Outcomes of refractory or relapsed Hodgkin lymphoma patients with post-autologous stem cell transplantation brentuximab vedotin maintenance: a French multicenter observational cohort study. Haematologica. 2022;107:1681\u20136.","journal-title":"Haematologica"},{"key":"1523_CR20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/hon.2939","volume":"40","author":"F Massaro","year":"2022","unstructured":"Massaro F, Pavone V, Stefani PM, Botto B, Pulsoni A, Patti C, et al. Brentuximab vedotin maintenance after autologous stem cell transplantation for Hodgkin lymphoma: a Fondazione Italiana Linfomi real-life experience. Hematol Oncol. 2022;40:31\u20139.","journal-title":"Hematol Oncol"},{"key":"1523_CR21","doi-asserted-by":"publisher","first-page":"3605","DOI":"10.1182\/blood.2022015423","volume":"139","author":"MG Mei","year":"2022","unstructured":"Mei MG, Lee HJ, Palmer JM, Chen R, Tsai NC, Chen L, et al. Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE. Blood. 2022;139:3605\u201316.","journal-title":"Blood"},{"key":"1523_CR22","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1182\/blood.2020009178","volume":"138","author":"RH Advani","year":"2021","unstructured":"Advani RH, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, et al. Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results. Blood. 2021;138:427\u201338.","journal-title":"Blood"},{"key":"1523_CR23","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1200\/JCO.21.01056","volume":"39","author":"AJ Moskowitz","year":"2021","unstructured":"Moskowitz AJ, Shah G, Schoder H, Ganesan N, Drill E, Hancock H, et al. Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma. J Clin Oncol. 2021;39:3109\u201317.","journal-title":"J Clin Oncol"},{"key":"1523_CR24","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1056\/NEJMoa2405888","volume":"391","author":"AF Herrera","year":"2024","unstructured":"Herrera AF, LeBlanc M, Castellino SM, Li H, Rutherford SC, Evens AM, et al. Nivolumab+AVD in advanced-stage classic Hodgkin\u2019s lymphoma. N Engl J Med. 2024;391:1379\u201389.","journal-title":"N Engl J Med"},{"key":"1523_CR25","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1182\/blood.2019000215","volume":"134","author":"P Armand","year":"2019","unstructured":"Armand P, Chen YB, Redd RA, Joyce RM, Bsat J, Jeter E, et al. PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. Blood. 2019;134:22\u20139.","journal-title":"Blood"},{"key":"1523_CR26","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1016\/S2352-3026(22)00318-0","volume":"10","author":"AF Herrera","year":"2023","unstructured":"Herrera AF, Chen L, Nieto Y, Holmberg L, Johnston P, Mei M, et al. Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial. Lancet Haematol. 2023;10:e14\u2013e23.","journal-title":"Lancet Haematol"},{"key":"1523_CR27","doi-asserted-by":"publisher","first-page":"7295","DOI":"10.1182\/bloodadvances.2023011205","volume":"7","author":"SH Desai","year":"2023","unstructured":"Desai SH, Spinner MA, Evens AM, Sykorova A, Bachanova V, Goyal G, et al. Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent era. Blood Adv. 2023;7:7295\u2013303.","journal-title":"Blood Adv"},{"key":"1523_CR28","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1182\/blood-2023-182143","volume":"142","author":"R Stuver","year":"2023","unstructured":"Stuver R, Drill E, Ganesan N, Baron K, Casper E, Chang T, et al. Outcomes for patients with classical Hodgkin lymphoma who relapse after autologous stem cell transplant in the era of novel therapies. Blood. 2023;142:3069.","journal-title":"Blood"},{"key":"1523_CR29","first-page":"2727","volume":"141","author":"MA Spinner","year":"2023","unstructured":"Spinner MA, Sica RA, Tamaresis JS, Lu Y, Chang C, Lowsky R, et al. Improved outcomes for relapsed\/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents. Blood. 2023;141:2727\u201337.","journal-title":"Blood"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01523-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01523-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01523-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T23:02:02Z","timestamp":1788908522000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01523-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1523"],"URL":"https:\/\/doi.org\/10.1038\/s41408-026-01523-w","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]},"assertion":[{"value":"15 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SHD: Onclive: Honoraria; CurioScience: Honoraria; Merck: Research Funding; Beigene: Research Funding, Incyte: Research Funding. All funding except CurioScience was made to the institution. MAS: Gilead\/Kite: Consultancy; ADC Therapeutics: Membership on an entity\u2019s Board of Directors or advisory committees. VB: Citius: Research Funding; Incyte: Research Funding. AME: Incyte: Consultancy, Honoraria; Daiichi Sankyo: Consultancy, Honoraria; Genentech: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Pharmacyclics: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria. BK: Genentech: Consultancy; Roche: Consultancy, Research Funding; BeiGene: Consultancy, Research Funding; AstraZeneca: Consultancy, Research Funding; Lilly: Consultancy; Novartis: Consultancy; Kite: Consultancy; AbbVie: Consultancy; Bristol Myers Squibb: Consultancy; Merck: Consultancy; ADCT: Consultancy. KD: BMS: Honoraria, Research Funding; Janssen: Honoraria, Research Funding; Kite-Gilead: Research Funding; Hoffman La-Roche: Research Funding; Genmab: Research Funding. VPK: Ipsen: Research Funding. Ansell: Affimed: Membership on an entity\u2019s Board of Directors or advisory committees, Research Funding; ADC Therapeutics: Research Funding; AstraZeneca: Research Funding; Bristol Myers Squibb: Research Funding; Pfizer: Research Funding; Regeneron Pharmaceuticals, Inc.: Research Funding; SeaGen: Research Funding; Takeda: Research Funding. HS: Incyte, Epizyme, Seattle Genetics, Loxo Oncology, Acerta: Research Funding; AbbVie, Seattle Genetics: Consultancy. Wagner-Johnston: Beigene: Consultancy; Merck: Research Funding; Genentech: Research Funding; AstraZeneca: Research Funding. Nowakowski: AbbVie Inc.: Consultancy; MorphoSys AG: Consultancy, Research Funding; TG Therapeutics Inc: Consultancy; ADC Therapeutics: Consultancy; Bantam Pharmaceutical, LLC: Consultancy; Segen: Consultancy; Bristol Myers Squibb: Consultancy, Research Funding; F. Hoffmann-La-Roche Limited: Consultancy; Constellation Pharmaceuticals: Consultancy; Kymera Therapeutics: Consultancy; Karyopharm Therapeutics: Consultancy; MEI Pharma: Consultancy; Fate Therapeutics: Consultancy; Genentech: Consultancy; Blueprint Medicines Corporation: Consultancy; Celgene Corporation: Consultancy, Research Funding; Debiopharm: Consultancy; Daiichi Sankyo: Consultancy; Zai Laboratory: Consultancy; Ryvu Therapeutics: Consultancy; Selvita Inc: Consultancy; Curis: Consultancy, Research Funding; Incyte Corporation: Consultancy. HM: Eli Lilly: Consultancy, Honoraria, Membership on an entity\u2019s Board of Directors or advisory committees; Janssen Cilag: Consultancy, Honoraria, Membership on an entity\u2019s Board of Directors or advisory committees; Takeda: Consultancy, Honoraria, Membership on an entity\u2019s Board of Directors or advisory committees; AstraZeneca: Honoraria, Membership on an entity\u2019s Board of Directors or advisory committees; Abbvie: Honoraria, Membership on an entity\u2019s Board of Directors or advisory committees; Bristol Myers Squibb: Honoraria, Membership on an entity\u2019s Board of Directors or advisory committees. DJ: Affimed, Daiichi Sankyo: Membership on an entity\u2019s Board of Directors or advisory committees; AstraZeneca, ATARA Biotherapeutics, Debio Pharma, LOXO Pharmaceuticals, MEI Pharma, Regeneron Pharmaceuticals, Inc., Seagen, Trillium Pharmaceuticals: Research Funding. KAB: BMS: Research Funding; Seattle Genetics: Research Funding. CD: FATE Therapeutics: Consultancy, Research Funding; Morphosys: Consultancy, Research Funding; Millenium: Research Funding; Merck: Consultancy, Research Funding; Gilead: Current equity holder in publicly-traded company, Research Funding; Genmab: Consultancy, Research Funding; Genentech\/Roche: Consultancy, Research Funding; Celgene: Consultancy, Research Funding; BMS: Consultancy, Membership on an entity\u2019s Board of Directors or advisory committees, Research Funding; AstraZeneca: Membership on an entity\u2019s Board of Directors or advisory committees; Incyte: Consultancy, Research Funding; MEI Pharma: Consultancy, Research Funding; I MAB: Consultancy, Current equity holder in private company; NYU Grossman School of Medicine\/Perlmutter Cancer Center at NYU Langone Health: Current Employment; OverT Therapeutics: Current equity holder in private company; AbbVie: Membership on an entity\u2019s Board of Directors or advisory committees, Research Funding; Seattle Genetics: Consultancy, Research Funding. VP: AbbVie: Consultancy; Eli Lilly: Consultancy; Novartis: Consultancy; Swixx: Consultancy, Speakers Bureau. RHA: Seattle Genetics: Research Funding; Cyteir: Research Funding; Regeneron: Research Funding; Autolus: Honoraria, Other: DSMB\/Advisory Boards; Gilead: Research Funding; Merck: Other: Steering committee, DSMB\/Advisory Boards, Research Funding; ADCT: Honoraria, Other: DSMB\/Advisory Boards; BeiGene: Honoraria, Other: DSMB\/Advisory Boards, Research Funding; Roche\/Genentech: Honoraria, Other: Steering committee, DSMB\/Advisory Boards, Research Funding.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"150"}}